Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGM BGM Group	$7.57 +0.9%	$10.76	$5.32 ▼ $17.17	$735.97M	1.26	49,183 shs	9,391 shs
STOK Stoke Therapeutics	$17.17 +1.5%	$12.28	$5.35 ▼ $17.61	$937.48M	1.15	790,391 shs	1.64 million shs
SXTC China SXT Pharmaceuticals	$1.58 -1.9%	$1.72	$0.95 ▼ $8.48	$183.33M	1.24	1.86 million shs	14,847 shs
TNGX Tango Therapeutics	$6.92 +0.6%	$5.78	$1.03 ▼ $12.02	$769.92M	1.64	1.76 million shs	640,095 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGM BGM Group	+0.81%	-8.59%	-7.18%	-34.90%	+749,999,900.00%
STOK Stoke Therapeutics	+24.98%	+28.40%	+40.22%	+75.60%	+19.34%
SXTC China SXT Pharmaceuticals	+1.32%	+7.33%	-3.01%	+3.21%	-81.37%
TNGX Tango Therapeutics	+1.78%	+5.85%	+12.97%	+352.63%	-23.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BGM BGM Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	4.161 of 5 stars	3.6	1.0	0.0	4.8	2.6	0.8	1.3
SXTC China SXT Pharmaceuticals	1.2354 of 5 stars	0.0	5.0	0.0	0.0	3.3	0.0	0.6
TNGX Tango Therapeutics	2.0224 of 5 stars	3.5	1.0	0.0	0.0	3.4	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BGM BGM Group	0.00	N/A	N/A	N/A
STOK Stoke Therapeutics	3.25	Buy	$25.17	46.57% Upside
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A
TNGX Tango Therapeutics	3.00	Buy	$10.33	49.33% Upside

Current Analyst Ratings Breakdown

Latest SXTC, BGM, TNGX, and STOK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	STOK Stoke Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00
8/13/2025	STOK Stoke Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $22.00
8/6/2025	TNGX Tango Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $10.00
7/18/2025	STOK Stoke Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
7/1/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
5/14/2025	STOK Stoke Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	STOK Stoke Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$47.00 ➝ $35.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BGM BGM Group	$26.85M	27.18	N/A	N/A	$7.34 per share	1.02
STOK Stoke Therapeutics	$36.56M	25.64	N/A	N/A	$4.32 per share	3.97
SXTC China SXT Pharmaceuticals	$1.74M	105.36	N/A	N/A	$21.35 per share	0.07
TNGX Tango Therapeutics	$24.30M	31.69	N/A	N/A	$1.21 per share	5.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BGM BGM Group	-$1.44M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	-$88.98M	$0.79	20.20	N/A	N/A	26.25%	19.41%	16.20%	N/A
SXTC China SXT Pharmaceuticals	-$3.30M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	-$130.30M	-$1.33	N/A	N/A	N/A	-599.11%	-79.72%	-49.30%	N/A

Latest SXTC, BGM, TNGX, and STOK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	STOK Stoke Therapeutics	-$0.57	-$0.40	+$0.17	-$0.40	$31.51 million	$13.82 million
8/5/2025	Q2 2025	TNGX Tango Therapeutics	-$0.35	-$0.35	N/A	-$0.35	$6.41 million	$3.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BGM BGM Group	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BGM BGM Group	N/A	1.82	1.45
STOK Stoke Therapeutics	N/A	8.41	8.41
SXTC China SXT Pharmaceuticals	0.01	3.54	3.40
TNGX Tango Therapeutics	N/A	4.75	4.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BGM BGM Group	N/A
STOK Stoke Therapeutics	N/A
SXTC China SXT Pharmaceuticals	5.02%
TNGX Tango Therapeutics	78.99%

Insider Ownership

Company	Insider Ownership
BGM BGM Group	58.66%
STOK Stoke Therapeutics	9.50%
SXTC China SXT Pharmaceuticals	3.95%
TNGX Tango Therapeutics	7.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BGM BGM Group	298	97.22 million	40.19 million	N/A
STOK Stoke Therapeutics	100	54.60 million	49.41 million	Optionable
SXTC China SXT Pharmaceuticals	90	116.03 million	111.45 million	Not Optionable
TNGX Tango Therapeutics	90	111.26 million	102.92 million	Optionable

SXTC, BGM, TNGX, and STOK Headlines

Recent News About These Companies

B. Riley Raises Earnings Estimates for Tango Therapeutics

August 14 at 8:02 AM | marketbeat.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by XTX Topco Ltd

August 14 at 3:26 AM | marketbeat.com

Equities Analysts Set Expectations for TNGX FY2025 Earnings

August 10, 2025 | americanbankingnews.com

Cantor Fitzgerald Analysts Lift Earnings Estimates for TNGX

August 9, 2025 | marketbeat.com

Q3 EPS Estimate for Tango Therapeutics Lifted by Analyst

August 8, 2025 | marketbeat.com

Wedbush Forecasts Stronger Earnings for Tango Therapeutics

August 8, 2025 | americanbankingnews.com

Guggenheim Boosts Tango Therapeutics (NASDAQ:TNGX) Price Target to $10.00

August 7, 2025 | marketbeat.com

Tango (TNGX) Q2 Revenue Drops 52%

August 5, 2025 | fool.com

Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Lags Revenue Estimates

August 5, 2025 | zacks.com

Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

August 5, 2025 | globenewswire.com

Tango Therapeutics (NASDAQ:TNGX) Trading Up 7.1% - What's Next?

August 2, 2025 | marketbeat.com

Wall Street Analysts Believe Tango Therapeutics (TNGX) Could Rally 61.46%: Here's is How to Trade

July 30, 2025 | zacks.com

Tango Therapeutics (TNGX) to Release Quarterly Earnings on Tuesday

July 30, 2025 | marketbeat.com

Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

July 29, 2025 | zacks.com

Tango Therapeutics (NASDAQ:TNGX) Shares Up 3% - Should You Buy?

July 24, 2025 | marketbeat.com

Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 9.1% - Time to Buy?

July 18, 2025 | marketbeat.com

TNGX - Tango Therapeutics Inc News - Morningstar

July 16, 2025 | morningstar.comM

Does Tango Therapeutics (TNGX) Have the Potential to Rally 75.89% as Wall Street Analysts Expect?

July 14, 2025 | zacks.com

Tango Therapeutics doses first patient in cancer drug combo trial

June 29, 2025 | uk.investing.com

Tango Therapeutics Shares Climb After First Patient Dosed in Pancreatic, Lung Cancer Trial

June 27, 2025 | marketwatch.com

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer

June 27, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTC, BGM, TNGX, and STOK Company Descriptions

BGM Group NASDAQ:BGM

$7.57 +0.07 (+0.93%)

Closing price 03:56 PM Eastern

Extended Trading

$7.50 -0.07 (-0.86%)

As of 04:10 PM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Stoke Therapeutics NASDAQ:STOK

$17.17 +0.26 (+1.54%)

Closing price 04:00 PM Eastern

Extended Trading

$17.27 +0.10 (+0.58%)

As of 06:07 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.58 -0.03 (-1.86%)

Closing price 04:00 PM Eastern

Extended Trading

$1.62 +0.04 (+2.85%)

As of 06:01 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Tango Therapeutics NASDAQ:TNGX

$6.92 +0.04 (+0.58%)

Closing price 04:00 PM Eastern

Extended Trading

$6.83 -0.09 (-1.30%)

As of 05:37 PM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time